AstraZeneca's Oncology Goal Separate Efficacy And Toxicity
Matthew Ellis, SVP of Early Oncology R&D for AstraZeneca, is helping lead the charge in what he calls the company's oncology revolution.
Source: clinicalleader.com
Fast, Ad-Free News Updates
Stay updated with breaking news from Plan Action Checklist. Real-time updates on events, politics, business and more.